HomeCompareCKPT vs PG

CKPT vs PG: Dividend Comparison 2026

CKPT yields 46.95% · PG yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CKPT wins by $284.7K in total portfolio value
10 years
CKPT
CKPT
● Live price
46.95%
Share price
$4.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$336.2K
Annual income
$64,770.40
Full CKPT calculator →
PG
Procter & Gamble
● Live price
2.92%
Share price
$144.73
Annual div
$4.23
5Y div CAGR
31.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.4K
Annual income
$9,955.44
Full PG calculator →

Portfolio growth — CKPT vs PG

📍 CKPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKPTPG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKPT + PG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKPT pays
PG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKPT
Annual income on $10K today (after 15% tax)
$3,990.61/yr
After 10yr DRIP, annual income (after tax)
$55,054.84/yr
PG
Annual income on $10K today (after 15% tax)
$248.27/yr
After 10yr DRIP, annual income (after tax)
$8,462.12/yr
At 15% tax rate, CKPT beats the other by $46,592.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKPT + PG for your $10,000?

CKPT: 50%PG: 50%
100% PG50/50100% CKPT
Portfolio after 10yr
$193.8K
Annual income
$37,362.92/yr
Blended yield
19.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PG right now

CKPT
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Price Target
$4.10
-3.8% upside vs current
Range: $4.10 — $4.10
Altman Z
-8.2
Piotroski
3/9
PG
Analyst Ratings
29
Buy
22
Hold
1
Sell
Consensus: Buy
Price Target
$167.67
+15.9% upside vs current
Range: $150.00 — $179.00
Altman Z
5.3
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKPT buys
0
PG buys
0
No recent congressional trades found for CKPT or PG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKPTPG
Forward yield46.95%2.92%
Annual dividend / share$2.00$4.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%31.1%
Portfolio after 10y$336.2K$51.4K
Annual income after 10y$64,770.40$9,955.44
Total dividends collected$264.2K$29.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$4.10$167.67

Year-by-year: CKPT vs PG ($10,000, DRIP)

YearCKPT PortfolioCKPT Income/yrPG PortfolioPG Income/yrGap
1← crossover$15,395$4,694.84$11,003$382.92+$4.4KCKPT
2$23,227$6,754.79$12,205$520.11+$11.0KCKPT
3$34,378$9,524.69$13,674$712.22+$20.7KCKPT
4$49,959$13,174.92$15,507$985.02+$34.5KCKPT
5$71,350$17,893.73$17,847$1,378.96+$53.5KCKPT
6$100,228$23,883.40$20,913$1,959.19+$79.3KCKPT
7$138,599$31,355.00$25,044$2,834.00+$113.6KCKPT
8$188,823$40,522.29$30,786$4,189.46+$158.0KCKPT
9$253,636$51,594.75$39,052$6,357.54+$214.6KCKPT
10$336,160$64,770.40$51,429$9,955.44+$284.7KCKPT

CKPT vs PG: Complete Analysis 2026

CKPTStock

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Full CKPT Calculator →

PGConsumer Staples

The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; and antiperspirants and deodorants, personal cleansing, and skin care products under the Olay, Old Spice, Safeguard, Secret, and SK-II brands. The Grooming segment provides shave care products and appliances under the Braun, Gillette, and Venus brand names. The Health Care segment offers toothbrushes, toothpastes, and other oral care products under the Crest and Oral-B brand names; and gastrointestinal, rapid diagnostics, respiratory, vitamins/minerals/supplements, pain relief, and other personal health care products under the Metamucil, Neurobion, Pepto-Bismol, and Vicks brands. The Fabric & Home Care segment provides fabric enhancers, laundry additives, and laundry detergents under the Ariel, Downy, Gain, and Tide brands; and air care, dish care, P&G professional, and surface care products under the Cascade, Dawn, Fairy, Febreze, Mr. Clean, and Swiffer brands. The Baby, Feminine & Family Care segment offers baby wipes, taped diapers, and pants under the Luvs and Pampers brands; adult incontinence and feminine care products under the Always, Always Discreet, and Tampax brands; and paper towels, tissues, and toilet papers under the Bounty, Charmin, and Puffs brands. The company sells its products primarily through mass merchandisers, e-commerce, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, high-frequency stores, pharmacies, electronics stores, and professional channels, as well as directly to consumers. The Procter & Gamble Company was founded in 1837 and is headquartered in Cincinnati, Ohio.

Full PG Calculator →
📬

Get this CKPT vs PG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKPT vs SCHDCKPT vs JEPICKPT vs OCKPT vs KOCKPT vs MAINCKPT vs KMBCKPT vs CLCKPT vs CHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.